Floatz logo

Zipalertinib

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

Jonsson Comprehensive Cancer CenterSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

1205 Active assets in the Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Onartuzumab
Hoffmann-La Roche
Phase 3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

Zipalertinib is also rated in:

AdjuvantDormant
B
Indicative ·
60 / 100
View asset →
Exon 20Dormant
B
Indicative ·
60 / 100
View asset →
lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →